Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.
European Journal of Cancer(2019)
摘要
•Adjuvant therapy with ipilimumab significantly improved the outcomes.•Compared with placebo, it prolonged RFS (hazard ratio [HR], 0.75), DMFS (HR, 0.76) and (OS; HR, 0.73).•The estimated absolute increase in the 7-year OS rate was 8.7%.•The benefit was sustained long term and consistent across subgroups.
更多查看译文
关键词
Ipilimumab,Adjuvant therapy,Phase III trial,Melanoma,Stage III,Long-term results
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络